Kite Pharma (KITE) Tops Q1 EPS by 44c

Kite Pharma (NASDAQ: KITE) reported Q1 EPS of ($1.28), $0.44 better than the analyst estimate of ($1.72). Revenue for the quarter came in at $9.8 million versus the consensus estimate of $12.31 million.

For earnings history and earnings-related data on Kite Pharma (KITE) click here.

You May Also Be Interested In

• Bristol-Myers Squibb and AstraZeneca said to discuss megamerger - can it happen?
• Marriott (MAR) Tops Q2 EPS by 14c, Misses on Revenue; Offers FY26 EPS Guidance
• Marriott shares fall on revenue miss despite earnings beat